Medicare Technical Corrections Legislation Doubtful After Rx Bill Passage
This article was originally published in The Gray Sheet
Executive Summary
The resolve of House Republican leaders to avoid re-opening the controversial Medicare law with a technical corrections bill in 2004 will limit DME competitive bidding opponents' options in repealing the provision
You may also be interested in...
United They Stand? Differing Device Platforms Share FDA Oversight Plank
Device advocacy groups credit a maturing industry presence on Capitol Hill, reflected by CEO-level participation, with achieving relevant Medicare reforms and a focus on FDA accountability
Evidence-Based Medicine Chasm: Can CMS, Industry Find Common Ground?
CMS' growing emphasis on evidence-based medicine to inform reimbursement decisions increasingly will lead manufacturers to conduct "high-quality" clinical trials, according to Chief Medical Officer Sean Tunis
DES Rates Sustained, CMS Exerting Price Pressures: Payment Recap
Johnson & Johnson/Cordis' efforts to raise the drug-eluting stent inpatient payment rates fell short in 2003, paving the way for the Cypher manufacturer and imminent competitor Boston Scientific (Taxus) to wage a concerted lobbying campaign this year